Truist Securities analyst Asthika Goonewardene downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Hold and lowers the price target from $8 to $3.
Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.